Zymergen was founded in 2013 by Jed Dean, Joshua Hoffman, and Zach Serber. The company has not officially endorsed a plan to participate in an IPO.

Zymergen is a science and material innovation company that develops and commercializes novel materials with a unique technology platform that combines biology, machine learning and automation. The company has raised nearly $900 million in Venture Capital funding from investors including Baillie Gifford, Baron Funds, Innovation Endeavors, Mission Bay Capital, Data Collective, Codon Capital, Two Sigma Investments, True Ventures, Threshold Ventures, Obvious Ventures, SoftBank Investment Advisers, Two Sigma Ventures, and Tao Capital Partners. Per company press releases, Zymergen last raised $300 million in September 2020 at a post-money valuation of approximately $1.75 billion.

Register for Details

For more details on financing and valuation for Zymergen, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Zymergen's ticker symbol?


Zymergen Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
9/8/2020 Series D $300MM raised $XXX.XX $XXX.XX
12/13/2018 Series C $434.5MM raised $XXX.XX $XXX.XX
10/10/2016 Series B $142.35MM raised $XXX.XX $XXX.XX
6/16/2015 Series A and A-1 $43.21MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Zymergen

Forge green plus iconForge green minus icon

What is Zymergen funding to date?

Zymergen has raised $920.06MM to date.
Forge green plus iconForge green minus icon

When was Zymergen founded?

Zymergen was founded in 2013.
Updated on: Sep 1, 2022